Spyridonidis, Alexandros; Labopin, Myriam; Gedde-Dahl, Tobias et al.
Validation of the transplant conditioning intensity (TCI) index for allogeneic hematopoietic cell transplantationBONE MARROW TRANSPLANTATION. 2023
Gerlach, Christina; Baus, Miriam; Gianicolo, Emilio et al.
What do bereaved relatives of cancer patients dying in hospital want to tell us? Analysis of free-text comments from the International Care of the Dying Evaluation (i-CODE) survey: a mixed methods approachSUPPORTIVE CARE IN CANCER. Bd. 31. H. 1. 2023
Bonilla, Sergio Armando Zapata; Fried, Marius; Singer, Susanne et al.
Working situation and burden of work limitations in sarcoma patients: results from the multi-center prospective PROSa studyJOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY. 2023
Mai, S; Weber, M
Würdeerleben und EntscheidungsfindungKern M, Gaspar M, Hach M (Hrsg). Palliative Care: Kernkompetenzen für die Pflegepraxis. Thieme Verlag 2023
Billaudelle, Fabian; Bayer, Oliver; Hechtner, Marlene et al.
"That was a tip from my physician"-Gender-specific pathways of patients and relatives to outpatient psychosocial cancer counselling centres-A qualitative studyPSYCHO-ONCOLOGY. Bd. 31. H. 6. 2022 S. 1022-1030
Rieger, Kathrin; De Filippi, Rosaria; Linden, Ola et al.
90-yttrium-ibritumomab tiuxetan as first-line treatment for follicular lymphoma: updated efficacy and safety results at an extended median follow-up of 9.6 yearsANNALS OF HEMATOLOGY. Bd. 101. H. 4. 2022 S. 781-788
Harrison, Claire; Heidel, Florian H.; Vannucchi, Alessandro M. et al.
A Phase Ib Dose-finding Study of Panobinostat and Ruxolitinib in MyelofibrosisHEMASPHERE. Bd. 6. H. 8. 2022
Hess, Georg; Huettmann, Andreas; Witzens-Harig, Mathias et al.
A phase II trial to evaluate the combination of pixantrone and obinutuzumab for patients with relapsed aggressive lymphoma: Final results of the prospective, multicentre GOAL trialBRITISH JOURNAL OF HAEMATOLOGY. Bd. 198. H. 3. 2022 S. 482-491
Birtel, M; Voss, R-H; Reinhard, K et al.
A TCR-like CAR promotes sensitive antigen recognition and controlled T cell expansion upon mRNA vaccinationCancer Res Commun. Bd. 2. H. 8. 2022 S. 827-41
Goldschmidt, Hartmut; Mai, Elias K.; Bertsch, Uta et al.
Addition of isatuximab to lenalidomide, bortezomib, and dexamethasone as induction therapy for newly diagnosed, transplantation-eligible patients with multiple myeloma (GMMG-HD7): part 1 of an open-label, multicentre, randomised, active-controlled, phase 3 trialLANCET HAEMATOLOGY. Bd. 9. H. 11. 2022 S. E810-E821